PAYER POLICY CHANGES

S3840 Insurance Policy Changes

HCPCS S3840 is officially defined as "Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2." HCPCS S3840 is referenced in 4 tracked payer policy changes from Excellus BlueCross BlueShield and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS S3840 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Watch S3840

Get one email when a payer policy names S3840, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

See every payer rule for S3840

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for S3840 in one place.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.